Aquestive Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q2 2024.
  • Aquestive Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was $55K.
  • Aquestive Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$15.2M, a 46.5% increase year-over-year.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$15.1M, a 64.1% increase from 2022.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.1M, a 21.3% decline from 2021.
  • Aquestive Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$34.7M, a 19.2% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$15.2M $55K +$4.26M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$19.5M -$8.96M -$4.35M -94.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$15.1M -$3.91M +$6.8M +63.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$21.9M -$2.38M +$6.48M +73.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 -$28.4M -$4.21M +$8.55M +67% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$36.9M -$4.61M +$5.13M +52.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$42.1M -$10.7M +$956K +8.19% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$43M -$8.85M -$885K -11.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$42.1M -$12.8M -$6.25M -95.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$35.9M -$9.74M -$1.21M -14.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 -$34.7M -$11.7M +$3.98M +25.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$38.7M -$7.97M +$5.81M +42.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$44.5M -$6.52M -$6.91M -1750% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 -$37.6M -$8.53M +$5.34M +38.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$42.9M -$15.6M -$5.74M -58% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 -$37.2M -$13.8M -$2.78M -25.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$34.4M $395K +$19.1M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$53.5M -$13.9M -$787K -6.02% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$52.7M -$9.9M +$2.42M +19.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$55.1M -$11M -$1.8M -19.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$53.3M -$18.7M +$14M +42.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$67.3M -$13.1M -$18.4M -346% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 -$48.9M -$12.3M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$9.21M -$19.6M -188% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 -$32.7M -$28.6M -706% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $5.31M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q3 2017 $10.4M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$4.06M Apr 1, 2017 Jun 30, 2017 10-Q 2018-09-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.